PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
| 07/31/2025 | 04/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -17.70% | 8.67% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.58% | 8.50% | |||
| Operating Income | 18.58% | -8.50% | |||
| Income Before Tax | -171.15% | 485.83% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -171.15% | 485.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -171.15% | 485.83% | |||
| EBIT | 18.58% | -8.50% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -177.75% | 461.67% | |||
| Normalized Basic EPS | -417.88% | -134.48% | |||
| EPS Diluted | -177.75% | 461.67% | |||
| Normalized Diluted EPS | -417.88% | -134.48% | |||
| Average Basic Shares Outstanding | -0.86% | -1.51% | |||
| Average Diluted Shares Outstanding | -0.86% | -1.51% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||